Ipamorelin: Research, FDA Status & What We Know
Why researchers became interested in a more selective growth-hormone signal—and why reports about deeper sleep, recovery, lean muscle and fat loss still run ahead of clinical proof.
Reviewed September 14, 2026 · Educational resource · Not medical advice
Awaiting editorial release. This page is readable but withheld from search engines until scientific, medical, legal and regulatory review are complete.
- FDA approval
- Not FDA-approved
- Evidence base
- Limited human studies; many promoted outcomes untested
- Regulatory watch
- FDA raised compounding safety concerns
Important: This page describes research interest and regulatory status. It does not recommend use, establish safety or effectiveness, or offer access to Ipamorelin.
Overview
The appeal is a signal—not a flood.
Ipamorelin is a synthetic five-amino-acid compound studied as a growth hormone secretagogue and ghrelin-receptor agonist. It is not growth hormone itself. Instead, it was designed to prompt a temporary release of the body’s own growth hormone.
That “pulse” is the center of the excitement. Early pharmacology suggested Ipamorelin could stimulate growth hormone with less spillover into ACTH and cortisol than older secretagogues in animal models. In a small study of healthy men, intravenous Ipamorelin produced a single episode of growth-hormone release.
That is an interesting biological signal. It is not proof that Ipamorelin improves sleep, burns fat, builds muscle, restores skin, reverses aging, or treats growth hormone deficiency.
Reader context: The language below explains why people search for Ipamorelin. It does not establish that the compound is safe, effective, available, or appropriate.
Reported experiences
What users commonly describe.
People who discuss Ipamorelin often reach for everyday language: “deeper sleep,” “better recovery,” “leaner,” “holding onto muscle,” or feeling as if their nighttime recovery is working again. Some also describe improved energy, training stamina, skin quality, mental clarity or libido.
- Sleep & recovery
- Users commonly connect Ipamorelin with deeper sleep and feeling more recovered. Human outcome trials have not established those benefits.
- Body composition
- Fat loss and lean-muscle retention are popular themes, but controlled human trials have not shown that Ipamorelin produces those outcomes.
- Tolerability talk
- Some users describe it as “cleaner” than older GH secretagogues; others report puffiness, bloating, hunger or injection-site symptoms. Anecdotes cannot define safety.
The most honest summary is that the reported experience is broader than the published evidence. The gap between the two is exactly what future trials would need to test.
Anecdotal—not clinical evidence: These themes come from user discussions. They do not predict an individual result or establish cause and effect.
Background
A selective secretagogue developed in the 1990s.
Researchers introduced Ipamorelin in 1998 as a potent, selective growth hormone secretagogue. The original selectivity experiments were largely conducted in rat pituitary cells, rats and swine—not in people seeking wellness, body-composition or anti-aging outcomes.
A 1999 dose-escalation study then characterized intravenous Ipamorelin in healthy male volunteers. Later development shifted toward postoperative ileus, where ghrelin-receptor activation was being explored as a way to restore gastrointestinal movement after bowel surgery.
- Class
- Synthetic pentapeptide; growth hormone secretagogue; ghrelin-receptor agonist.
- Human pharmacology
- A small healthy-volunteer study measured pharmacokinetics and a short growth-hormone response.
- Largest trial
- A 117-patient phase 2 trial in postoperative ileus did not show significant efficacy versus placebo.
Claims & proposed mechanisms
What a growth-hormone pulse can—and cannot—tell us.
Ghrelin-receptor activation
Ipamorelin acts at the growth hormone secretagogue receptor, often called GHSR-1a. That receptor biology can trigger pituitary growth-hormone release and also intersects with gastrointestinal signaling.
A measurable GH response
In healthy male volunteers receiving intravenous infusions, growth hormone rose to a peak and then declined. Measuring that hormone response establishes pharmacology, not a long-term health benefit.
Selectivity needs careful wording
The frequently repeated “no cortisol or prolactin” claim comes mainly from preclinical comparisons. It should not be presented as a guaranteed human effect or proof of a superior safety profile.
Evidence caution: A pathway is not a patient outcome. No controlled human evidence establishes Ipamorelin as a treatment for fat loss, muscle gain, sleep, skin elasticity, mood, anxiety, libido or healthy aging.
Evidence review
What published studies actually found.
- Preclinical pharmacology · 1998
Selective GH release was demonstrated mainly in animal systems
Raun and colleagues reported growth-hormone release in rat pituitary cells, rats and swine. In swine, Ipamorelin did not significantly raise ACTH or cortisol beyond the GHRH comparator. This helped define the research hypothesis, but it does not establish selectivity, benefit or safety in routine human use.
- Human PK/PD · 1999 · small dose-escalation study
Intravenous Ipamorelin produced a short growth-hormone pulse
Eight healthy men were studied at each of five infusion levels. Concentrations were dose-proportional, the reported terminal half-life was about two hours, and growth hormone peaked at roughly 0.67 hours before falling to very low levels by six hours. The study measured hormone response—not sleep, fat loss, muscle, skin or wellbeing.
- Phase 2 RCT · 2014 · 117 surgical patients
The postoperative-ileus trial missed its efficacy endpoints
Adults undergoing bowel resection received intravenous Ipamorelin or placebo. Median time to a tolerated meal favored Ipamorelin numerically, but the difference was not statistically significant, and key and secondary efficacy analyses found no significant benefit. This hospital study does not validate subcutaneous wellness use.
Clinical context
Symptoms deserve a diagnosis, not a peptide shortcut.
Fatigue, poor sleep, reduced exercise recovery, body-composition change and concern about growth hormone can have many causes. Sleep disorders, low energy intake, thyroid disease, medication effects, menopause, depression, overtraining, diabetes and true pituitary disease require very different evaluations.
Start with the concern
Define the symptom, timeline, severity, red flags, medical history and what has already been tried.
Test the real hypothesis
Growth hormone deficiency cannot be diagnosed from wellness symptoms or a single random GH level. Endocrine testing belongs with a qualified clinician.
Separate routes and products
Evidence from a controlled intravenous study does not automatically transfer to compounded subcutaneous, oral or nasal products.
Reader context: Find GLP-1 Care Now does not provide peptide access: no prescribing, product sourcing, dosing instructions, reconstitution guidance, stacking plan or investigational-peptide waitlist is offered through this research library.
Regulatory watch
Where Ipamorelin stands in the United States.
Ipamorelin and Ipamorelin acetate are not components of an FDA-approved drug. FDA has identified Ipamorelin acetate as a bulk substance that may present significant safety risks for compounding, citing immunogenicity, aggregation, peptide-related impurities, characterization challenges and insufficient safety information for certain injectable routes.
In October 2024, FDA’s Pharmacy Compounding Advisory Committee voted 0 yes, 12 no and 1 abstention on adding either Ipamorelin free base or Ipamorelin acetate to the 503A Bulks List. That committee vote was a recommendation in a compounding review—not an FDA drug approval decision.
Ipamorelin acetate separately remains in FDA’s 503B Category 2 for bulk substances that raise significant safety risks. As of this review, FDA has not announced an upcoming meeting to add Ipamorelin to the 503B Bulks List. A meeting planned before the end of February 2027 concerns five other substances under 503A, not Ipamorelin. Category 2 is neither FDA approval nor the ordinary Category 1 enforcement discretion, and the live FDA calendar and lists should be re-checked on the review date.
Primary sources
Common questions
Ipamorelin FAQ
Frequently asked questions
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide studied as a growth hormone secretagogue and ghrelin-receptor agonist. It can trigger a temporary release of endogenous growth hormone, but it is not growth hormone itself and is not an FDA-approved medication.
Why are researchers interested in Ipamorelin?
Researchers became interested in Ipamorelin because early preclinical work suggested relatively selective growth-hormone release compared with older secretagogues. That selectivity hypothesis is scientifically interesting, but it does not establish broad wellness benefits or a superior human safety profile.
Does Ipamorelin increase growth hormone?
A small 1999 dose-escalation study in healthy men found that intravenous Ipamorelin produced a short episode of growth-hormone release. The study characterized pharmacology; it did not prove improvements in sleep, body composition, recovery, skin, mood or longevity.
Does Ipamorelin improve sleep or recovery?
Deeper sleep and better recovery are common user-reported themes, but controlled human trials have not established Ipamorelin as an effective treatment for sleep or exercise recovery. Reported experiences should not be treated as proof.
Does Ipamorelin help with fat loss or muscle gain?
Fat loss, lean-muscle retention and improved body composition are widely promoted claims, but they have not been established in controlled human Ipamorelin trials. A growth-hormone response is not the same as a proven change in fat mass, muscle mass or performance.
Does Ipamorelin raise cortisol or prolactin?
The popular claim that Ipamorelin avoids cortisol and prolactin effects comes mainly from preclinical comparisons, including animal experiments. It should not be stated as a guaranteed effect in humans or used to imply that Ipamorelin is risk-free.
What did the human Ipamorelin trials show?
A small healthy-volunteer study measured intravenous pharmacokinetics and a growth-hormone pulse. A separate phase 2 trial in 117 bowel-surgery patients found no statistically significant improvement over placebo in postoperative-ileus efficacy endpoints. Neither study established common wellness claims.
What side effects or safety concerns are associated with Ipamorelin?
Human safety data are limited and route-specific. FDA has cited concerns involving immunogenicity, aggregation, peptide-related impurities, uncertain product characterization and insufficient safety information for certain injectable routes. In its review, FDA also discussed hyperglycemia, hypokalemia and deaths observed in an intravenous surgical study, while noting that causality for the deaths was unclear.
Is Ipamorelin FDA-approved?
No. Ipamorelin and Ipamorelin acetate are not components of an FDA-approved drug. An FDA advisory committee’s review of whether a bulk substance belongs on a compounding list is separate from the drug-approval process.
Can Ipamorelin be combined with CJC-1295?
Ipamorelin and CJC-1295 are often discussed together online, but popularity is not clinical validation. This page does not recommend stacking, and controlled evidence has not established an FDA-approved Ipamorelin and CJC-1295 combination.
What is the Ipamorelin dosage?
There is no FDA-approved Ipamorelin dosage for the wellness, sleep, recovery or body-composition uses discussed here. Find GLP-1 Care Now does not publish dosing, cycling, injection, reconstitution, storage or self-administration protocols for investigational compounds.
How long does Ipamorelin take to work?
There is no clinically established timeline for the promoted sleep, recovery, muscle or fat-loss outcomes. A small intravenous study measured a growth-hormone peak at about 0.67 hours, but that laboratory signal does not define when a person would feel or experience a health benefit.
Related research
- CJC-1295A GHRH analogue often discussed alongside Ipamorelin, and why a popular pairing is not a studied combination.
- TesamorelinA GHRH analogue with a narrow FDA-approved indication, and the limits of transferring that approval.
- DSIP / EmideltideThe limits of sleep research and current U.S. compounding review.
This page is an educational research summary. It is not medical advice, not a recommendation to use any compound, and not an offer of access to one. Talk to a licensed clinician about your own care.
Find GLP-1 Care Now is owned by Athena Certification Center LLC. JourneyMeds is the founding sponsor. Sponsorship does not change organic provider rankings or editorial conclusions. Read the full ownership and advertising disclosure.
Last reviewed September 14, 2026. Regulatory status is checked on the review date and can change afterwards; follow the primary sources above for the current position.